AbbVie adds stem cell-based ADC in $5.8bn Stemcentrx acquisition – BioPharma-Reporter.com
BioPharma-Reporter.com |
AbbVie adds stem cell-based ADC in $5.8bn Stemcentrx acquisition
BioPharma-Reporter.com Management also spoke about the future potential of Stemcentrx's proprietary technology which leverages stem cell biology to identify and screen potential targets against live tumor tissue to more predictably advance discovery and development of new … AbbVie buys cancer stem cell therapy firm for $5.8B; shares off 3% premarket AbbVie to Expand Oncology Presence Through Acquisition of Stemcentrx and its Novel, Late-Stage Rova-T Compound … The second-largest acquisition in the history of venture capital happened today — here's why a pharma giant paid … |
